View
220
Download
1
Category
Tags:
Preview:
Citation preview
Stem cell therapy in cardiac practice
Dr Sajeer K TSenior resident, Department of Cardiology, Govt. Medical College, Kozhikode.
1
Background
2
Cardiovascular disease leading cause of morbidity and mortality ➔ worldwide
Despite advances in Mx and cath-based therapy for AMI 1-year mortality: 13% 5-year prognosis for patients with HF: 50%.
LV systolic dysfunction: major determinant of prognosis associated with significant loss of cardiomyocytes
(Irreversible heart post mitotic organ)➔
Abdul M. Mozid et al. British Medical Bulletin 2011; 98: 143–159
Stem cell therapy
3
Clinical trials focused on 3 main situations:
Acute MI (with the hope of preventing LVSD) Chronic heart failure secondary to previous MI DCM (non ischemic cardiomyopthy)
Areas of discussion: 1. Stem cell types used in cardiac repair
2. Methods of cell delivery in clinical practice
3. Clinical trial evidence to date
Stem cell ?
4
Stem cell a cell with a unique capacity to produce unaltered daughter cells (self-renewal) & to
generate specialized cell types (potency)
Self-renewal symmetric division:
two stem cellstwo cells destined for differentiation
asymmetric division: one stem cell and one differentiating cell
Signature characteristic of the stem cell
5
Types of stem cells
6
Stem cells : 2 types
Somatic stem cells : BM, brain, liver, skeletal & dermal tissue in vitro proliferative ability is limited
Pluripotent stem cells : Embryonic stem cells, embryonic germ cells embryonic carcinoma cells, induced pluripotent stem (iPS) Exhibit pluripotency
Traditional view Current evidence ➲
7
Traditional view: heart is a terminally differentiated post mitotic organ
Current evidence: heart is not a terminally differentiated post mitotic organ
4 sources of cells : for new cardiomyocytes after birth
1. Adult cardiomyocytes (mononucleated)2. Bone marrow–derived cardiac stem or progenitor cells3. Embryonic epicardium derived cells4. Niches of cardiac stem or cardiac progenitor cells (CPCs)
Stem Cells 2007; 25:589. Cell 2009 138;257–270.
Different cell types investigated for use in cardiac repair
8
Abdul M. Mozid et al. British Medical Bulletin 2011; 98: 143–159
Heart - self-renewing organ
9
Myocyte regeneration occurs throughout organism lifespan
Cardiac niches contain stem cells after activation ➔ ➔ give rise to myocytes and vascular structures
Piero Anversa, Jan Kajstura, Annarosa Leri. Circulation. 2006;113:1451-1463
Cardiac Stem or Progenitor cells (CSC or CPC)
10
niche of primitive cells present in human heart
possess the ability to form cardiomyocytes, endothelial cells (ECs), smooth muscle cells (SMCs)
Different classes of CPCs : based on cell surface markers
1. c-Kit+ cells
2. Sca-1+ cells
3. side population cells (SP)
4. cells expressing the protein Islet-1 (transcription factor)
Cardiac progenitor cell classes
11
c-kit positive cell Sca-1 positive cell SP cells Cardiospheres Epicardial progenitors
Hierarchy of CPC growth and differentiation
12
Asymmetrical division of a CSC ➨ a daughter CSC and a daughter cardiac progenitor (CPg)
CPg gives rise to - Myocyte progenitor (MPg )& precursor (MPr) - EC progenitor (EPg) & precursor (EPr) - SMC progenitor (SMPg) & precursor (SMPr) Precursors ➨ transient amplifying cells ➨ divide and differentiate into mature myocytes, ECs, and SMCs. CSCs are lineage-negative cells : express only c-kit, MDR1, or Sca-1. Progenitors express stem cell antigens and transcription factors of cardiac cells but do not exhibit specific cytoplasmic proteins Precursors possess stem cell antigens, transcription factors, membrane& cytoplasmic proteins typical of myocytes, ECs, and SMCs
Hierarchy of CPC growth and differentiation
13
Cardiac Stem Cells and Myocardial Diseases
14
Role of cardiac stem cells in the advanced stages of HF: - to modulate endogenous CPCs to regenerate cardiac muscle and to create new blood vessel formation
Ventricular remodeling progressive chamber dilation and thinning of the walls➔ Myocardial regeneration reverse this process➔ ➔ transforming a dilated failing heart into a normal, functionally competent organ
Bone marrow stem cells
15
Bone marrow–derived stem cells: - best studied cells - used in clinical trials in MI and/or idiopathic DCM
Bone marrow progenitor cells:- hematopoietic stem cells (HSCs)- side population cells (SP cells)
(expression of the Abcg2 transporter and allowing export of Hoechst dye)
- mesenchymal stem cells (MSCs)- multipotential adult progenitor cells (MAPCs)
Inducible Pluripotent Stem Cells (iPSCs)
16
Adult stem cells successfully reprogrammed back to an ➔ undifferentiated pluripotent state (by inserting 4 genes: Oct3/4, Sox2, KL4 and c-Myc into differentiated somatic cells)
Morphological phenotype of ES cells
Same differentiation potential as ES cells ( in vivo and in vitro) - able to form all three germ layers
Functioning cardiomyocytes produced from iPSCs➔
Inducible Pluripotent Stem Cells (iPSCs)
17
Reprogramming factors ➨ introduced in vitro Established iPS cells ➨ differentiate into various cell types
Generation of iPS cells from somatic cells
Circulation. 2010;122:80-87
18
iPS demonstrate pluripotent features
Circulation. 2009;120:408-416
Cell types and mode of delivery of cells for cardiac repair
19
A : Cell types used for cardiovascular repair
B: Delivery strategies used in the clinical setting for cell therapy
EPCs = endothelial progenitor cells iPS cells = induced pluripotent SCs MSCs = mesenchymal stem cells SP cells = side population cells
20
Summary of cell types used in clinical trials and future perspective
Circulation. 2010;121:325-335
Method of delivery of stem cells
21
Intracoronary infusion of cells: - most popular mode of cell delivery - after AMI
Intramyocardial injection: - performed in patients with chronic heart failure secondary to IHD
- transendocardial injections (catheter-based) - transepicardial injections (during open heart surgery)
Mechanisms of action
22
Progenitor cells: improve functional recovery of infarcted or failing myocardium 1. Direct or indirect improvement of revascularization2. Paracrine factors released by progenitor cells may inhibit cardiac apoptosis, affect remodeling, or enhance endogenous repair (eg: by tissue-resident PCs)3. Differentiation into cardiomyocytes may contribute to cardiac regeneration.
Homing of BM-derived stem cells to the myocardium
23
Homing of BM-derived stem cells to the myocardium: - fate of bone marrow-derived stem cells is determined by the microenvironment that they enter
Mobilization and homing
24
Homing is mediated by : AdhesionTransmigration Invasion
Prerequisite for cell-based therapies
25
Summary of prerequisite for cell-based therapies
Circulation. 2010;121:325-335
26
Stem cell therapy in acute MI
Stem cell therapy in acute myocardial infarction
27
Most of the trials used intracoronary delivery of BMSCs following successful stenting of the infarct-related artery
Surrogate markers used to assess efficacy of cell therapy: - Improvements in the LVEF
- Reduction in size of scar tissue - Reduction in cardiac volume
Post infarction heart failure: - results from ventricular remodeling processes - characterized by progressive expansion of the infarct area and dilation of the LV cavity
28
Major goal to reverse LV remodeling: - enhancement of regeneration of cardiac myocytes - stimulation of neovascul. within the infarct area
4 main randomized controlled trials (RCTs) - published with positive findings
1. TOPCARE-AMI ( Circulation- 2002) 2. BOOST trial ( Lancet - 2004)3. REPAIR-AMI trial ( EJM - 2006) 4. FINCELL (Eur Heart - 2008)
Randomized control trials of intracoronary BMSC therapy following acute myocardial infarction
29
TOPCARE-AMI :Transplantation of Progenitor Cells and Regeneration Enhancement in AMI
30Birgit Assmus et al. Circulation. 2002;106:3009-3017
LV Function Assessed by Analysis of LV Angiography in the Cell Therapy Group
31
Demonstrated potential beneficial effect of BSMC therapy following AMI with improvement in the LVEF from 51.6+ 9.6% to 60.1+8.6% at 4 months
TOPCARE-AMI :Transplantation of Progenitor Cells and Regeneration Enhancement in AMI
32Birgit Assmus et al. Circulation. 2002;106:3009-3017
Left panel (A): LV angiography before CPC therapy
Right panel (B): at 4-month follow-up
TOPCARE-AMI :Transplantation of Progenitor Cells and Regeneration Enhancement in AMI
33Birgit Assmus et al. Circulation. 2002;106:3009-3017
Echocardiographic wall motion score index at rest (initial basal) and during low-dose dobutamine stimulation (initial 10 g dobutamine) at baseline before progenitor cell therapy and
at rest at 4-month follow-up (follow-up basal).
TOPCARE-AMI :Transplantation of Progenitor Cells and Regeneration Enhancement in AMI
34Birgit Assmus et al. Circulation. 2002;106:3009-3017
BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST trial)
35Lancet 2004; 364: 141–48
BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST trial)
36Lancet 2004; 364: 141–48
BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST trial)
37Lancet 2004; 364: 141–48
BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST trial)
38
Lancet 2004; 364: 141–48
BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST trial)
39
Representative colour-coded images showing systolic wall motion at baseline and 6 months' follow-up in two patients.
Both patients had A/C AWMI.
Bright colours: good systolic wall motion. Dark colours : poor wall motion (expressed in mm).
Note improved functional recovery in patient treated with BMCs.
Lancet 2004; 364: 141–48
Reinfusion of Enriched Progenitor Cellsand Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial
40N Engl J Med 2006;355:1210-21.
Enrollment and outcomes
Reinfusion of Enriched Progenitor Cellsand Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial
41
N Engl J Med 2006;355:1210-21.
Reinfusion of Enriched Progenitor Cellsand Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial
42
Placebo n=92 BMC n=95 P value
N Engl J Med 2006;355:1210-21.
Reinfusion of Enriched Progenitor Cellsand Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial
43N Engl J Med 2006;355:1210-21.
Reinfusion of Enriched Progenitor Cellsand Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial
44N Engl J Med 2006;355:1210-21.
Panel A:Interaction between baseline LVEF and the absolute change in LVEF
Panel B:Interaction between the timing of intracoronary infusion of BMC or placebo after reperfusion therapy and the absolute change in LVEF
Reinfusion of Enriched Progenitor Cellsand Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) trial
45N Engl J Med 2006;355:1210-21.
Intracoronary administration of BMC is associated with improved recovery of left ventricular contractile function in patients with acute myocardial infarction
Conclusion
Effects of I/C injection of mononuclear BMCs on LV function, arrhythmia risk profile, and restenosis after lytic therapy of AMI
46
- FINCELL Investigators
European Heart Journal (2008) 29, 2723–2732
Aim: To assess the efficacy and safety of bone marrow cell (BMC) therapy after thrombolytic therapy of an acute STEMI
Methods: Patients with STEMI treated with thrombolysis followed by PCI
(2–6 days after STEMI ) Intracoronary BMCs (n= 40) placebo medium (n= 40) (collected & prepared 3–6 h prior PCI)
Injected into the infarct artery immediately after stenting
Effects of I/C injection of mononuclear BMCs on LV function, arrhythmia risk profile, and restenosis after lytic therapy of AMI
47
- FINCELL Investigators
European Heart Journal (2008) 29, 2723–2732
At 6 months: BMC group : greater absolute increase of global LVEF than placebo (measured by angiography or 2-D echo) No differences observed between the groups in - adverse clinical events - arrhythmia risk variables - MLD of stented coronary lesion
Effects of I/C injection of mononuclear BMCs on LV function, arrhythmia risk profile, and restenosis after lytic therapy of AMI
48
Effects of I/C injection of mononuclear BMCs on LV function, arrhythmia risk profile, and restenosis after lytic therapy of AMI
49
Conclusion :Intracoronary BMC therapy is associated with an
improvement of global LVEF and neutral effects on arrhythmia risk profile and restenosis of the stented coronary lesions in patients after lytic therapy of STEMI
- FINCELL Investigators
European Heart Journal (2008) 29, 2723–2732
RCTs with neutral findings
50
LEUVEN-AMI study1: - No changes in global LVEF after BMSC infusion
ASTAMI trial2 : - No significant effect on the LVEF, LV volumes, or infarct size
HEBE trial3 : - No changes in global or regional LV systolic function after BMSC therapy
3Alexander Hirsch et al. Eur Heart J 2010
1Janssens et al. Lancet 2006;367:113–212 Lunde K et al. N Eng J Med 2006;355:1199–209
51
Reasons for the inconsistent findings:
1. Variations in the number of cells delivered
2. Timing of delivery after AMI
3. Differences in the cell isolation protocol
52
Stem cell therapy in chronic ischemic heart failure
Stem cell therapy in chronic ischemic heart failure
53
Skeletal myoblasts and BMSCs : 2 cell types investigated in chronic heart failure & severely impaired LV function secondary to previous MI
Skeletal myoblasts transplantation: : initially investigated in patients undergoing open heart surgery
Myoblasts are obtained from culture of a prior muscle biopsy
Injected in to epicardium at the time of surgery
54
Clin
ical t
rials
of s
tem
cel
l the
rapy
for c
hron
ic isc
hem
ic he
art f
ailu
reClinical trials of stem cell therapy for chronic ischemic
heart failure
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial
55
1st randomized placebo-controlled study of Myoblast transplantation
Cells ➔ injected into epicardium within scarred areas during open heart surgery
Patients with LVSD secondary to previous MI and who required CABG
Circulation. 2008;117:1189-1200
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial
56Circulation. 2008;117:1189-1200
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial
57
A : Time to first MACE
B: Time to first ventricular arrhythmia
Circulation. 2008;117:1189-1200
study was prematurely stopped no improvement in regional or global LVEF higher number of arrhythmic events
STAR-heart study
58
The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study
only limited data available on the effectiveness of BMC’s in chronic HF
investigated ventricular hemodynamics, geometry, and contractility as well as the long-term clinical outcome of BMC treated patients with reduced LVEF due to chronic ischaemic cardiomyopathy
largest study to date of BMSC therapy in chronic ischaemic HF
Bodo-Eckehard Strauer et al. European Journal of Heart Failure (2010) 12, 721–729
STAR-heart study
59
STAR-heart study
60Bodo-Eckehard Strauer et al. European Journal of Heart Failure (2010) 12, 721–729
STAR-heart study
61
EF over time in the BMC group compared with the control group
Bodo-Eckehard Strauer et al. European Journal of Heart Failure (2010) 12, 721–729
STAR-heart study
62
Effect of BMC therapy on survival in patients with chronic ischaemic cardiomyopathy
Bodo-Eckehard Strauer et al. European Journal of Heart Failure (2010) 12, 721–729
STAR-heart study
63
STAR-heart study-conclusion
64
5-year follow-up intracoronary BMSC therapy ➔ associated with significant improvement in the LVEF and exercise capacity
significant decrease in long-term mortality
Bodo-Eckehard Strauer et al. European Journal of Heart Failure (2010) 12, 721–729
65
Stem cell therapy in dilated cardiomyopathy
Stem cell therapy in dilated cardiomyopathy
66
A Pilot Trial : to assess potential effects of selective intracoronary bone marrow–
derived progenitor cell infusion in patients with non-ischemic DCM
Intracoronary administration of BMCs ➔ shown to improve coronary micro vascular function in IHD
Coronary micro-vascular dysfunction is implicated in the pathogenesis and prognosis of noni-schemic DCM
Ulrich Fischer-Rasokat et al. Circ Heart Fail. 2009;2:417-423
TOPCARE-DCM
Transplantation of Progenitor Cells and Functional Regeneration Enhancement Pilot Trial in Patients with Non-ischemic DCM
TOPCARE-DCM
67
Individual changes of the extent of hypokinetic area (A), severity of hypokinesia (B), and ejection fraction (C) between baseline and 3-month
follow-up
TOPCARE-DCM
68
Individual changes of the adenosine-induced minimal vascular resistance index of the BMC-treated LAD for all 24 patients between baseline and 3-
month follow-up
Conclusion:
Intracoronary administration of BMC seems to be associated with improvements in cardiac contractile and micro vascular function in patients with DCM
Summary and future directions
69
Past decade has seen an explosion in clinical studies investigating the safety and efficacy of stem cell therapy for heart diseases.
Safety of stem cell therapy has been demonstrated uniformly in the vast majority of the studies.
Beneficial effects of cell therapy have been demonstrated : AMI, chronic ischaemic HF and DCM.
Need for larger RCTs with longer term follow-up assessing morbidity and mortality as primary outcome measures.
70
Recommended